Axsome Therapeutics Presents New Data and Post-Hoc Analyses

New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode

Related Keywords

United States , Toronto , Ontario , Canada , Florida , New York , Texas , Tampa , Rakesh Jain , Roger Mcintyre , Darren Opland , Greg Mattingly , Mark Jacobson , Nasdaq , Us Department Of Health , Human Services , Corporate Communications , Texas Tech University School Of Medicine , World Trade Center , American College Of Neuropsychopharmacology , Axsome Therapeutics Inc , Clinical Professor Of Psychiatry At Washington University , Mental Health Indicators , World Health Organization , National Survey On Drug , Midwest Research Group , University Of Toronto , Drug Administration , Department Of Psychiatry , National Institutes Of Health , American College , Major Depressive Disorder Using , Depressive Symptoms , Patients With One Prior Treatment Failure , Evolve Long Term , Associate Clinical Professor , Washington University , Midwest Research , Withdrawal Symptoms After Discontinuation , Results From , Clinical Professor , Texas Tech University School , National Institutes , Breakthrough Therapy , Prescribing Information , Boxed Warning , Axsome Therapeutics , Key Substance Use , Drug Use , Published October , Dis Treat , Region ,